NVS-SM1

• CAT Number: I001984
• CAS Number: 1562338-42-4
• Molecular Formula: C₂₂H₂₇N₅O₂
• Molecular Weight: 393.49
• Purity: ≥95%
• Synonyms: Branaplam; LMI 070; LMI070; NVS-SM1
• Target: Membrane Transporter/Ion Channel
• Solubility: DMSO: ≤ 6.12 mg/mL
• Storage: Store at -20C
• IUPAC Name: 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol
• InChI: InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)
• InChIKey: STWTUEAWRAIWJG-UHFFFAOYSA-N
• SMILES: CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C

NVS-SM1（Cat No.:I001984）is a small molecule inhibitor developed by Novartis, primarily studied for its potential in cancer treatment. It targets and inhibits the activity of a specific protein, often related to the modulation of immune checkpoints or tumor progression. By interfering with the tumor microenvironment or immune response, NVS-SM1 aims to enhance the body’s ability to fight cancer cells. While preclinical studies have shown promise, its exact mechanisms and therapeutic potential are still under investigation. Further clinical trials are required to determine its efficacy, safety, and potential as a cancer therapy.

Overview of Clinical Research

Originator: Novartis
Class: Cyclohexanes; Pyrazoles; Pyridazines; Small molecules
Mechanism of Action: Survival of motor neuron 2 protein modulators
Orphan Drug Status: No
New Molecular Entity: Yes